Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

Obesity and metabolic syndrome

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (3) ACSL Family (1) Acyltransferase (1) AMPK (2) Apoptosis (1) Biochemical Assay Reagents (1) Cannabinoid Receptor (3) DAGL (1) Drug Derivative (1) Endogenous Metabolite (3) Environmental Pollutants (2) Free Fatty Acid Receptor (1) Glycosidase (2) IPK Superfamily (1) MAGL (1) PPAR (3) Reference Standards (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (4) Metabolic Disease (21) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-N7075

Inulin 4 Publications Verification	Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; Enhancing the intestinal barrier function and reducing endotoxin translocation; Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].

HY-124529

Lunularin	11β-HSD Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Lunularin is an inhibitor of 11β-hydroxysteroid dehydrogenase 1, with an IC₅₀ of 45.44 μM and a K_i of 35.8 μM against human 11β-HSD1, and an IC₅₀ of 17.39 μM and a K_i of 10.31 μM against rat 11β-HSD1. Lunularin upregulates the transcription levels of Sirt1 and Hmox1 genes in the liver. Lunularin reduces food intake and body weight gain, and decreases blood glucose levels in mice fed a high-fat diet. Lunularin inhibits LPS-induced TLR4-mediated NF-κB pathway activation and nitric oxide production. Lunularin inhibits the proliferation and colony formation of renal cancer and colon cancer cells, and exhibits cancer cell-specific cytotoxicity. Lunularin binds to the steroid-binding site of human 11β-HSD1 and the steroid/NADPH-binding region of rat 11β-HSD1, but does not inhibit 11β-HSD2 or mouse 11β-HSD1. Lunularin can be used in research related to diet-induced obesity, renal cancer, colorectal cancer, inflammatory diseases and metabolic syndrome .

HY-110079

TNP	IPK Superfamily	Cancer
TNP is a competitive, reversible inhibitor of IP6K1 and IP3K, with IC₅₀s of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP competitively binds to the ATP binding site of IP6K, inhibits the generation of 5-IP7, and thus relieves the inhibition of 5-IP7 on the AKT signaling pathway. TNP can enhance insulin sensitivity and promote thermogenesis in adipose tissue. TNP cannot effectively pass through the blood-brain barrier and is mainly used in the study of obesity, type 2 diabetes, and metabolic syndrome. However, TNP also inhibits CYP3A4 and may need further optimization[1][2][3].

HY-W009417

Cedryl acetate	Environmental Pollutants Glycosidase	Metabolic Disease
Cedryl acetate is an orally active α-glucosidase inhibitor with an IC₅₀ of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .

HY-177704

ACSL5-IN-1	ACSL Family Drug Derivative	Metabolic Disease Cancer
ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer .

HY-124314

LEI-106	MAGL DAGL	Metabolic Disease
LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a K_i of 0.8 μM for ABHD6, and an IC₅₀ of 18 nM and a K_i of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (K_i=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .

HY-16434

DGAT1-IN-3	Acyltransferase	Metabolic Disease
DGAT1-IN-3 is a potent, selective and orally bioavailable inhibitor of DGAT-1, with IC₅₀s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. DGAT1-IN-3 could be used to research of obesity, dyslipidemia, and metabolic syndrome .

HY-156010

PPARγ-IN-2	PPAR	Metabolic Disease
PPARγ-IN-2 (Compound 5a) is a PPARγ inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC₅₀: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue .

HY-W414548

7α,27-Dihydroxycholesterol	Others	Neurological Disease Metabolic Disease
7α,27-Dihydroxycholesterol is an oxysterol characterized by its oxidized side chains and is produced through the hydroxylation of 27-Hydroxycholesterol (27-OHC); it serves as a metabolite of interest in lipidomic analyses of various pathological conditions, including neurological diseases, Smith-Lemli-Opitz syndrome, obesity metabolic syndrome, and diabetes. Notably, levels of 7α,27-di-OHC decrease following lipopolysaccharide activation, and it also functions as a ligand for Epstein-Barr virus-induced gene 2 (EBI2). Additionally, 7α,27-di-OHC exists as a structural isomer of 7α,25-dihydroxycholesterol (7α25-OHC).

HY-N7394

Galbacin (3S)-Zuonin A	AMPK	Metabolic Disease Cancer
Galbacin ((3S)-Zuonin A), the epimer of (-)-Zuonin A (HY-N7394A), is a AMPK activator. Galbacin can be isolated from Myristica fragrans (nutmeg). Galbacin stimulates AMPK enzyme in differentiated C2C12 cells. Galbacin also has anticancer activity, and inhibits the proliferation of lymphocyte and tumor cells. Galbacin prevents weight gain in diet-induced mice model. Galbacin can be used for metabolic syndrome (including obesity and type-2 diabetes) and caners research .

HY-N7687

Caulophyllogenin	PPAR	Metabolic Disease Inflammation/Immunology
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation .

HY-P4815

Prokineticin 2 Isoform 2 (human)	Endogenous Metabolite	Neurological Disease Metabolic Disease
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity .

HY-147037

AMPK activator 7	AMPK	Cardiovascular Disease Metabolic Disease
AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC₅₀ of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension .

HY-178857

CB1 antagonist 6	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 6 (Compound 11jE2) is an orally active CB1R antagonist, with an IC₅₀ value of 23 nM. CB1 antagonist 6 significantly reduces food intake and body weight, improves glucose tolerance and insulin resistance, and decreases serum ALT and AST levels in diet-induced obese (DIO) mice, demonstrating hepatoprotective effects. CB1 antagonist 6 can be used for the study of metabolic syndrome (obesity, diabetes) .

HY-123090

11β-HSD1-IN-12	11β-HSD	Metabolic Disease
11β-HSD1-IN-12 is a 11β-HSD1 inhibitor (Example 21 in reference patent). 11β-HSD1 regenerates active glucocorticoids from inactive forms and is important in regulating intracellular glucocorticoid concentration. 11β-HSD1-IN-12 can be used in the research of obesity and metabolic syndrome .

HY-U00397

CB1 antagonist 1	Cannabinoid Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
CB1 antagonist 1 is an antagonist of CB1 receptor, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.

HY-120943

K-111 BM 17.0744	PPAR	Metabolic Disease
K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome .

HY-W009417R

Cedryl acetate (Standard)	Reference Standards Glycosidase Environmental Pollutants	Metabolic Disease
Cedryl acetate (Standard) is the analytical standard of Cedryl acetate. This product is intended for research and analytical applications. Cedryl acetate is an orally active α-glucosidase inhibitor with an IC₅₀ of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .

HY-156328

NSC 48160	Apoptosis	Cancer
NSC 48160 inhibits the growth of the pancreatic cancer cells with IC₅₀s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders .

HY-14156

11β-HSD1-IN-15	11β-HSD	Metabolic Disease
11β-HSD1-IN-15 is an inhibitor of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1). 11β-HSD1-IN-15 blocks the conversion of corticosterone to cortisol by binding to the active site of the 11β-HSD1 enzyme. 11β-HSD1-IN-15 can be used to investigate the role of 11β-HSD1 enzymes IN the development of metabolic syndrome, obesity, cognitive decline and type 2 diabetes .

HY-W002852

3-Amino-3-(p-tolyl)propionic acid 3-Amino-3-(4-methylphenyl)propanoic acid	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
3-Amino-3-(p-tolyl) propionic acid (3-Amino-3-(4-methylphenyl) propanoic acid) is a GPR40 agonist. 3-Amino-3-(p-tolyl) propionic acid is used for research on type 2 diabetes, obesity, metabolic syndrome and lipid disorders .

HY-P11612

ATS-9R	Biochemical Assay Reagents	Metabolic Disease
ATS-9R is a peptide consisting of an adipocyte-targeting sequence and D-form 9-arginine. ATS-9R selectively transfects mature adipocytes by binding to prohibitin. ATS-9R allows an adipocyte-targeted gene delivery in vitro and in vivo. ATS-9R can be used for the development of an adipocyte-targeted gene carrier. ATS-9R can be used for the study of obesity as well as obesity-induced metabolic syndromes .

Cat. No.	상품명

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library	4,779 compounds
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 4,779 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

4,779 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 4,779 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Cat. No.	상품명	Target	Research Area